Muscle News and Research

RSS

Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV.

10 Nov 2011

Mathematical model accurately predicts horizontal gaze movements of eye

In one respect, handling a computer mouse is just like looking in the rearview mirror: well established movements help the brain to concentrate on the essentials. But just a simple gaze shift to a new target bears the possibility of an almost infinite number of combinations of eye and head movement: how fast do we move eye and head? How much does the eye rotate, how much the head? Until now, it was unclear why the brain chooses a particular movement option from the set of all possible combinations.

10 Nov 2011

Study needed to identify most effective exercise to improve balance among older people

Good balance and mobility are essential to help you perform most activities involved in every-day life, as well as many recreational pursuits. Keeping your balance is a complex task, involving the co-ordination between a person's muscles and sensors which detect balance and are part of the nervous system.

9 Nov 2011

Sex of patient plays a relevant role in recovery from facial paralysis

Research work drawn up by specialists from the Department of Plastic, Reconstructive and Aesthetic Surgery at the University of Navarra Hospital has shown that, after surgical treatment for facial paralysis through using muscular transplant and nervous transposition (connection of facial muscle to a nerve different from the injured facial nerve), the brain of a woman - in comparison to that of a male - manages to adapt itself better, recovers the spontaneous smile and has a greater time period available for repairing the paralysis.

9 Nov 2011

Sleep paralysis more frequent among students and psychiatric patients

What do Moby Dick, the Salem witch trials and alien abductions all have in common? They all circle back to sleep paralysis.

9 Nov 2011

Treatments can help most HCM patients

Most of the 600,000 Americans with hypertrophic cardiomyopathy (HCM) -- a genetic heart muscle disease -- can live normal life spans, according to the first science-based guideline for diagnosing and treating this disorder.

9 Nov 2011

Tufts University professor earns March of Dimes Foundation award for tissue development

A new approach to studying tissue development has earned Catherine K. Kuo, Ph.D., an assistant professor of biomedical engineering in Tufts University's School of Engineering, the Basil O'Connor Starter Scholar Award from the March of Dimes Foundation.

9 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

Pfizer's Toviaz Study A0221048 for overactive bladder meets primary endpoint

Pfizer Inc. announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency.

9 Nov 2011

FDA accepts Genentech's vismodegib NDA for review

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

9 Nov 2011

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

8 Nov 2011

A person's stroke risk profile may help identify future cognitive problems

A new study shows a person's stroke risk profile, which includes high blood pressure, smoking, and diabetes, may also be helpful in predicting whether a person will develop memory and thinking problems later in the life.

8 Nov 2011

New breakthrough facelifting technique

In their November issue, the Aesthetic Surgery Journal published a new breakthrough facelifting technique which gives superior results with fewer complications than current techniques in practice. The pioneer of this new Minimal Access Deep Plane Extended Vertical "MADE" Facelift is NY Facial Plastic and Reconstructive Surgeon, Dr. Andrew Jacono.

7 Nov 2011

IFNa-kinoid shows promise against lupus

The first study to show results using active immunotherapy against the signaling protein interferon alpha in the treatment of lupus will be presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Mouse anti-aging study generates expert commentary

Age related changes like wrinkles, muscle wasting and cataracts could be delayed in mice, say researchers in the US. They achieved the feat by removing old cells that had stopped dividing. These accumulate naturally with age. The scientists believe their findings could eventually “really have an impact” in the care of the elderly. Experts said the results were “fascinating”, but should be taken with a bit of caution.

6 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

Baxter launches NUMETA emulsion for infusion in Europe

Baxter International Inc. announced today the European launch of NUMETA (emulsion for infusion).

From Baxter International Inc. 4 Nov 2011

Slowing aging by cleaning away old cells: Study

Researchers have found a novel way of reversing the aging process. They found that a special category of cells, known as senescent cells, are bad actors that promote the aging of the tissues. Cleansing the body of the cells, they hope, could postpone many of the diseases of aging. This could pave the way for drugs that would keep human tissues healthier longer, but it is unclear until further testing is done whether such drugs could eventually help people live longer.

3 Nov 2011

FDA EMDAC votes to recommend approval of Merck's VYTORIN for pre-dialysis CKD

Merck, known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck's VYTORIN (ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease.

3 Nov 2011

Eliminating senescent cells could prevent or delay onset of age-related disorders

Researchers at Mayo Clinic have shown that eliminating cells that accumulate with age could prevent or delay the onset of age-related disorders and disabilities. The study, performed in mouse models, provides the first evidence that these "deadbeat" cells could contribute to aging and suggests a way to help people stay healthier as they age.

3 Nov 2011